Poseida Therapeutics (NASDAQ:PSTX) Receives Neutral Rating from BTIG Research

BTIG Research restated their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note published on Tuesday morning,Benzinga reports.

A number of other analysts also recently weighed in on PSTX. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday. HC Wainwright reissued a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday.

Poseida Therapeutics Trading Up 228.0 %

Shares of PSTX opened at $9.38 on Tuesday. The stock has a market capitalization of $914.17 million, a PE ratio of -14.89 and a beta of 0.54. The company’s fifty day moving average is $2.90 and its 200 day moving average is $2.97. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $9.41.

Institutional Investors Weigh In On Poseida Therapeutics

Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after purchasing an additional 297,500 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Poseida Therapeutics by 177.3% in the first quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock worth $201,000 after buying an additional 40,245 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Poseida Therapeutics by 280.3% during the 1st quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after acquiring an additional 21,138 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in Poseida Therapeutics during the 1st quarter valued at $33,000. Institutional investors own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.